This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

S&P Capital IQ Initiates Coverage On Yew Bio-Pharm Group In Standard & Poor's Factual Stock Reports

NEW YORK, Aug. 19, 2013 /PRNewswire/ -- S&P Capital IQ announced today that it has commenced Standard & Poor's Factual Stock Report coverage on Yew Bio-Pharm Group.

(Logo: http://photos.prnewswire.com/prnh/20130819/NY65529LOGO )

(Logo: http://photos.prnewswire.com/prnh/20130524/NY19925LOGO )

Yew Bio-Pharm Group, Inc. (YEWB), through its operating entity, Harbin Yew Science and Technology Development Co., Ltd., grows and sells yew trees, sells yew raw materials used in the manufacture of traditional Chinese medicine (TCM), and makes and sells products made from yew timber in China. Raw material from the species of yew tree that the company grows contains taxol, and TCM containing taxol has been approved as a traditional Chinese medicine in China for secondary treatment of certain cancers. Products made from yew trees include potted yew trees for display in homes and offices, and handicrafts.

The company uses a patented, accelerated growth technology to speed the growth and maturity and commercialization of yew trees and believes that it is one of the few companies possessing a permit to sell them.

The company operates in three reportable business segments: the TCM raw materials segment, consisting of the production and sale of yew raw materials used in the manufacture of TCM; the yew tree segment, consisting of the growth and sale of yew tree seedlings and mature trees, including potted miniature yew trees; and the handicrafts segment, consisting of the manufacture and sale of furniture and handicrafts made of yew timber. All of the company's operations are conducted in the People's Republic of China.

During the three months ended June 30, 2013, Yew Bio-Pharm sold approximately 7,880 kg (17,336 lb) of TCM raw materials as compared to approximately 7,050 kg (15,510 lb) of TCM raw materials in the three months ended June 30, 2012. During the six months ended June 30, 2013, Yew Bio-Pharm sold approximately 13,207 kg (29,066 lb) of TCM raw materials as compared to approximately 11,400 kg (25,080 lb) of TCM raw materials in the six months ended June 30, 2012. During the three months ended June 30, 2013, Yew Bio-Pharm sold approximately 38,000 pieces of yew seedlings and trees as compared to approximately 88,000 pieces of yew seedlings and trees in the three months ended June 30, 2012.  During the six months ended June 30, 2013, Yew Bio-Pharm sold approximately 218,000 pieces of yew seedlings and trees as compared to approximately 180,000 pieces of yew seedlings and trees in the six months ended June 30, 2012. 

Yew Bio-Pharm sells yew trees primarily to state-owned enterprises and private businesses for reforestation in Heilongjiang Province and Jilin Province, in Northeast China.

Standard & Poor's Factual Stock Report coverage on Yew Bio-Pharm Group will also be accessible on an ongoing basis to the investment community by scores of buy-side institutions and sell-side firms that utilize S&P Capital IQ research and information platforms daily. Millions of self-directed investors also have access to the report via their e-brokerage accounts.  Please visit http://www.yewchina.com for additional information.

About Standard & Poor's Factual Stock ReportsCurrently profiling approximately 500 issuers, Standard & Poor's Factual Stock Reports, produced by S&P Capital IQ, increase market awareness of issuers in the investment community with insightful commentary and key statistics and information.  Standard & Poor's Factual Stock Reports provide factual research coverage about company fundamentals and business prospects, thereby enabling information about covered companies to reach a wide investor audience of Buy and Sell-side investors. Updated weekly with the latest pricing, trading volume, and other data, the reports include recent developments, a financial review, key operating information, industry and peer comparisons, institutional holdings analysis, Street Consensus and opinions, performance charts, business summary, fundamental data, and news. Because coverage of these reports is underwritten by the issuer, S&P Capital IQ does not offer investment opinions concerning the advisability of investing in these stocks.

Standard & Poor's Factual Stock Reports are produced separately from any other analytic activity of S&P Capital IQ or related organizations.  S&P Capital IQ does not trade on its own account.

Stock quotes in this article: MHFI 

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 16,424.85 +162.29 1.00%
S&P 500 1,862.31 +19.33 1.05%
NASDAQ 4,086.2250 +52.0640 1.29%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs